JP6375112B2 - テネクテプラーゼの医薬組成物 - Google Patents

テネクテプラーゼの医薬組成物 Download PDF

Info

Publication number
JP6375112B2
JP6375112B2 JP2013545634A JP2013545634A JP6375112B2 JP 6375112 B2 JP6375112 B2 JP 6375112B2 JP 2013545634 A JP2013545634 A JP 2013545634A JP 2013545634 A JP2013545634 A JP 2013545634A JP 6375112 B2 JP6375112 B2 JP 6375112B2
Authority
JP
Japan
Prior art keywords
tnk
tenecteplase
pharmaceutical composition
treatment
ais
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013545634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502608A (ja
JP2014502608A5 (enExample
Inventor
マヘシュワリ クマール ミシュラ
マヘシュワリ クマール ミシュラ
プリティランジャン バンダリ
プリティランジャン バンダリ
サンジャイ シン
サンジャイ シン
Original Assignee
ジェノヴァ バイオファーマシューティカルズ リミテッド
ジェノヴァ バイオファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6375112(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェノヴァ バイオファーマシューティカルズ リミテッド, ジェノヴァ バイオファーマシューティカルズ リミテッド filed Critical ジェノヴァ バイオファーマシューティカルズ リミテッド
Publication of JP2014502608A publication Critical patent/JP2014502608A/ja
Publication of JP2014502608A5 publication Critical patent/JP2014502608A5/ja
Application granted granted Critical
Publication of JP6375112B2 publication Critical patent/JP6375112B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013545634A 2010-12-23 2011-12-16 テネクテプラーゼの医薬組成物 Active JP6375112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23
IN3516/MUM/2010 2010-12-23
PCT/IN2011/000863 WO2012085933A1 (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Publications (3)

Publication Number Publication Date
JP2014502608A JP2014502608A (ja) 2014-02-03
JP2014502608A5 JP2014502608A5 (enExample) 2018-04-26
JP6375112B2 true JP6375112B2 (ja) 2018-08-15

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545634A Active JP6375112B2 (ja) 2010-12-23 2011-12-16 テネクテプラーゼの医薬組成物

Country Status (17)

Country Link
US (2) US20130323227A1 (enExample)
EP (1) EP2654770B1 (enExample)
JP (1) JP6375112B2 (enExample)
CN (1) CN103391785A (enExample)
AU (1) AU2011346515B2 (enExample)
BR (1) BR112013015914B1 (enExample)
CO (1) CO6721059A2 (enExample)
DK (1) DK2654770T3 (enExample)
EA (1) EA026017B1 (enExample)
ES (1) ES2687850T3 (enExample)
LT (1) LT2654770T (enExample)
MX (1) MX356199B (enExample)
MY (1) MY171723A (enExample)
NZ (1) NZ611706A (enExample)
PL (1) PL2654770T3 (enExample)
PT (1) PT2654770T (enExample)
WO (1) WO2012085933A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209767B1 (en) * 2014-10-21 2020-08-05 Gennova Biopharmaceuticals Ltd. A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase)
CN110913890A (zh) * 2017-05-16 2020-03-24 国家医疗保健研究所 用于治疗急性缺血性中风的方法和药物组合物
US20210214702A1 (en) * 2018-06-01 2021-07-15 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
NZ574767A (en) * 2006-08-29 2012-02-24 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
US8916148B2 (en) * 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
EP2654770B1 (en) 2018-07-11
US20130323227A1 (en) 2013-12-05
ES2687850T3 (es) 2018-10-29
US9943575B2 (en) 2018-04-17
AU2011346515A1 (en) 2013-07-04
AU2011346515B2 (en) 2017-01-19
US20160310580A1 (en) 2016-10-27
BR112013015914A2 (pt) 2016-10-11
DK2654770T3 (en) 2018-10-29
NZ611706A (en) 2015-04-24
EA201300746A1 (ru) 2013-11-29
BR112013015914B1 (pt) 2021-06-08
MY171723A (en) 2019-10-24
WO2012085933A1 (en) 2012-06-28
PL2654770T3 (pl) 2018-12-31
EA026017B1 (ru) 2017-02-28
CO6721059A2 (es) 2013-07-31
MX356199B (es) 2018-05-18
LT2654770T (lt) 2018-09-10
JP2014502608A (ja) 2014-02-03
PT2654770T (pt) 2018-10-19
EP2654770A4 (en) 2014-05-21
EP2654770A1 (en) 2013-10-30
MX2013007381A (es) 2013-08-29
CN103391785A (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
US20250179447A1 (en) Solubilized apyrases, methods and use
EA026410B1 (ru) Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
NL8601354A (nl) Nieuwe samenstelling.
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
JP6375112B2 (ja) テネクテプラーゼの医薬組成物
TW202525331A (zh) 人類重組精胺酸酶 １ 之產生方法及其用途
US7070958B2 (en) Methods of making pro-urokinase mutants
JP3805378B2 (ja) ｒＤＳＰＡα１の製造の方法
CN108218978B (zh) 一种重组白细胞介素18及其制备方法与应用
JP2907447B2 (ja) 抗血栓剤
CN100580082C (zh) 一种重组葡激酶冻干制剂、制备方法和应用
CN108559740B (zh) 重组安克洛酶及工业规模制备方法和治疗急性脑梗的应用
CN112210003A (zh) 一种重组载脂蛋白j及其类似物的晶体结构及应用
CN1326357A (zh) 治疗镰刀形红细胞贫血病及地中海贫血病的方法
CN110016471B (zh) 重组安克洛酶及工业规模制备和纯化方法及其组合物
JPH04295500A (ja) 新規な巨核球増幅因子とその製法
US20210138035A1 (en) C3 fusion protein and methods of making and using thereof
JPS6338327B2 (enExample)
CN117467021A (zh) 一种组织型纤溶酶原激活剂的重组蛋白及其制备方法与用途
EP2565269B1 (en) Method for producing high-purity soluble thrombomodulin
EP0475719A2 (en) Platelet derived growth regulating peptide
NZ229611A (en) A bolus formulation containing at least 12.5 mu of t-pa

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161005

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161209

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180723

R150 Certificate of patent or registration of utility model

Ref document number: 6375112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250